Martin Seule1,2,3, Christopher Sikorski4, Oliver Sakowitz5, Gord von Campe6, Edgar Santos5, Berk Orakcioglu5, Andreas Unterberg5, Emanuela Keller4. 1. Neurointensive Care Unit, University Hospital and University of Zurich, Zurich, Switzerland. martin.seule@kssg.ch. 2. Department of Neurosurgery, University Heidelberg, Heidelberg, Germany. martin.seule@kssg.ch. 3. Department of Neurosurgery, Kantonsspital St. Gallen, St. Gallen, Switzerland. martin.seule@kssg.ch. 4. Neurointensive Care Unit, University Hospital and University of Zurich, Zurich, Switzerland. 5. Department of Neurosurgery, University Heidelberg, Heidelberg, Germany. 6. Department of Neurosurgery, University Graz, Graz, Austria.
Abstract
OBJECTIVE: To evaluate an intraparenchymal probe for intracranial pressure (ICP) and temperature (TEMP) monitoring as well as determination of cerebral hemodynamics using a near-infrared spectroscopy (NIRS) and indocyanine green (ICG) dye dilution method (NIRS-ICP probe). METHODS: The NIRS-ICP probe was applied after aneurysmal subarachnoid hemorrhage if multimodal monitoring was established due to poor neurological condition. ICP and TEMP values were obtained from ventricular catheters and systemic temperature sensors. Repeated NIRS-ICG measurements (2 injections within 30 min) were performed daily for determination of cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time of ICG (mttICG). Secondary neurologic dysfunction was defined as brain tissue oxygen tension <20 mmHg and/or lactate/pyruvate ratio >35 obtained from cerebral probing. RESULTS: A total of 128 NIRS-ICG measurements were performed in ten patients. The correlation coefficients between ICP and TEMP values obtained with the NIRS-ICP probe and values from routine monitoring were r = 0.72 and r = 0.96, respectively. The mean values were 30.3 ± 13.6 ml/100 g/min for CBF, 3.3 ± 1.2 ml/100 g for CBV, and 6.8 ± 1.6 s for mttICG. The coefficients of variation from repeated NIRS-ICG measurements were 10.9 % for CBF, 11.7 % for CBV, and 3.8 % for mttICG. The sensitivity for detection of secondary neurologic dysfunction was 85 % and the specificity 83 % using a CBF-threshold of 25 ml/100 g/min. CONCLUSION: Multimodal monitoring using the NIRS-ICP probe is feasible with high reproducibility of measurement values and the ability to detect secondary neurologic dysfunction. No safety concerns exist for the routine clinical use of the NIRS-ICP probe.
OBJECTIVE: To evaluate an intraparenchymal probe for intracranial pressure (ICP) and temperature (TEMP) monitoring as well as determination of cerebral hemodynamics using a near-infrared spectroscopy (NIRS) and indocyanine green (ICG) dye dilution method (NIRS-ICP probe). METHODS: The NIRS-ICP probe was applied after aneurysmal subarachnoid hemorrhage if multimodal monitoring was established due to poor neurological condition. ICP and TEMP values were obtained from ventricular catheters and systemic temperature sensors. Repeated NIRS-ICG measurements (2 injections within 30 min) were performed daily for determination of cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time of ICG (mttICG). Secondary neurologic dysfunction was defined as brain tissue oxygen tension <20 mmHg and/or lactate/pyruvate ratio >35 obtained from cerebral probing. RESULTS: A total of 128 NIRS-ICG measurements were performed in ten patients. The correlation coefficients between ICP and TEMP values obtained with the NIRS-ICP probe and values from routine monitoring were r = 0.72 and r = 0.96, respectively. The mean values were 30.3 ± 13.6 ml/100 g/min for CBF, 3.3 ± 1.2 ml/100 g for CBV, and 6.8 ± 1.6 s for mttICG. The coefficients of variation from repeated NIRS-ICG measurements were 10.9 % for CBF, 11.7 % for CBV, and 3.8 % for mttICG. The sensitivity for detection of secondary neurologic dysfunction was 85 % and the specificity 83 % using a CBF-threshold of 25 ml/100 g/min. CONCLUSION: Multimodal monitoring using the NIRS-ICP probe is feasible with high reproducibility of measurement values and the ability to detect secondary neurologic dysfunction. No safety concerns exist for the routine clinical use of the NIRS-ICP probe.
Authors: P Vajkoczy; H Roth; P Horn; T Lucke; C Thomé; U Hubner; G T Martin; C Zappletal; E Klar; L Schilling; P Schmiedek Journal: J Neurosurg Date: 2000-08 Impact factor: 5.115
Authors: Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel Journal: Neurocrit Care Date: 2011-09 Impact factor: 3.210
Authors: Jose I Suarez; Adnan I Qureshi; Abutaher B Yahia; Parak D Parekh; Rafael J Tamargo; Michael A Williams; John A Ulatowski; Daniel F Hanley; Alexander Y Razumovsky Journal: Crit Care Med Date: 2002-06 Impact factor: 7.598
Authors: Peter Le Roux; David K Menon; Giuseppe Citerio; Paul Vespa; Mary Kay Bader; Gretchen M Brophy; Michael N Diringer; Nino Stocchetti; Walter Videtta; Rocco Armonda; Neeraj Badjatia; Julian Böesel; Randall Chesnut; Sherry Chou; Jan Claassen; Marek Czosnyka; Michael De Georgia; Anthony Figaji; Jennifer Fugate; Raimund Helbok; David Horowitz; Peter Hutchinson; Monisha Kumar; Molly McNett; Chad Miller; Andrew Naidech; Mauro Oddo; DaiWai Olson; Kristine O'Phelan; J Javier Provencio; Corinna Puppo; Richard Riker; Claudia Robertson; Michael Schmidt; Fabio Taccone Journal: Neurocrit Care Date: 2014-12 Impact factor: 3.210
Authors: Martin N Stienen; Carlo Serra; Lennart H Stieglitz; Niklaus Krayenbühl; Oliver Bozinov; Luca Regli Journal: Acta Neurochir (Wien) Date: 2017-11-13 Impact factor: 2.216
Authors: Andrew R Stevens; Clarissa A Stickland; Georgia Harris; Zubair Ahmed; Pola Goldberg Oppenheimer; Antonio Belli; David J Davies Journal: Cells Date: 2022-04-05 Impact factor: 6.600